Real-World Outcomes of Adjuvant Pembrolizumab for Renal Cell Carcinoma: The Potential Role of PD-L1 as a Prognostic Biomarker

Hiroki Ishihara, Takayuki Nakayama, Hironori Fukuda, Nanaka Katsurayama, Yuki Nemoto, Shinsuke Mizoguchi, Hiroaki Shimmura, Yasunobu Hashimoto, Atsuko Seki, Kazuhiko Yoshida, Junpei Iizuka, Tsunenori Kondo, Yoji Nagashima, Toshio Takagi · 2026

Read Real-World Outcomes of Adjuvant Pembrolizumab for Renal Cell Carcinoma: The Potential Role of PD-L1 as a Prognostic Biomarker by Hiroki Ishihara, Takayuki Nakayama, Hironori Fukuda, Nanaka Katsurayama, Yuki Nemoto, Shinsuke Mizoguchi, Hiroaki Shimmura, Yasunobu Hashimoto, Atsuko Seki, Kazuhiko Yoshida, Junpei Iizuka, Tsunenori Kondo, Yoji Nagashima, Toshio Takagi (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13427842.txt.

Description

Ishihara and co-authors examined real-world results for 53 Japanese patients given pembrolizumab, an immune checkpoint drug, after surgery for kidney cancer at high risk of returning. Patients were selected using the criteria of the KEYNOTE-564 trial, and the team also tested whether tumor PD-L1 staining predicted recurrence in 35 available samples.

Median follow-up was 18.9 months, and 45 patients, or 85 percent, fell into the intermediate-to-high risk category at enrollment. Eleven patients, or 21 percent, experienced recurrence, while the 12-month disease-free survival rate stood at 90.5 percent overall. Patients whose tumors scored high on PD-L1 recurred far more often, 44 percent versus 5 percent for low scorers in this series. Severe adverse events affected 13 patients, and 11 stopped treatment because of side effects, which the authors call manageable.

Catalog record

CREATORHiroki Ishihara, Takayuki Nakayama, Hironori Fukuda, Nanaka Katsurayama, Yuki Nemoto, Shinsuke Mizoguchi, Hiroaki Shimmura, Yasunobu Hashimoto, Atsuko Seki, Kazuhiko Yoshida, Junpei Iizuka, Tsunenori Kondo, Yoji Nagashima, Toshio Takagi
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE30 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13427842

Browse the full library · About the Tower of Babel